ERBB2 and breast neoplasm: Of note, we recently demonstrated that the immunetargeting of xCT is able to potentiate a viral vector-based vaccine against Her2 in constraining Her2+ breast tumor growth as well as in decreasing CSC frequency and metastatic events in preclinical mouse models [14].